Atacicept is a medicine for adults with IgA nephropathy, a kidney disease. It works by calming the immune cells that make the faulty antibodies that harm the kidneys, which lowers protein in the urine. It is given as a shot under the skin.
Every report comes from a Lived member, sent anonymously.
Have you tried Trutakna (Atacicept) for IgA Nephropathy?
Atacicept, sold as Trutakna, is a prescription injection for adults with IgA nephropathy (IgAN), a kidney disease in which an abnormal form of the antibody IgA forms clumps that lodge in the kidney's filters and inflame them. Over years, that damage can cause protein to leak into the urine and kidney function to decline. Trutakna is approved for adults with primary IgAN (IgAN not caused by another disease) whose disease is at risk of getting worse. The US approval, granted in 2026, is an accelerated approval. It rests on the drug's ability to lower the amount of protein in the urine, which tends to track with how fast IgAN progresses. When it was approved, the label said it had not yet been shown that the drug slows the loss of kidney function over the long term, and a confirmatory trial result is needed to keep the approval. In its main study, people took atacicept in addition to their usual kidney-protecting treatment: the highest tolerated dose of an ACE inhibitor or ARB (blood pressure medicines that also reduce protein leakage), and often an SGLT2 inhibitor, a diabetes medicine class that also protects the kidneys. It is meant to add to that foundation, not replace it. Its safety and effectiveness have not been established in anyone under 18.
The abnormal IgA that drives IgAN is made by B cells, the immune cells that produce antibodies. Two signaling proteins, called BAFF (B-cell activating factor, also known as BLyS) and APRIL (a proliferation-inducing ligand), help keep these cells alive and producing antibodies. Atacicept is a lab-made protein that binds to both signals and blocks them. With less BAFF and APRIL signaling, the body makes less of the faulty IgA. In the main study, blood levels of that faulty IgA fell by about two thirds within months. Less of it reaching the kidneys means less ongoing inflammation, which shows up as less protein in the urine. Because the drug lowers antibody production more broadly, levels of other protective antibodies (IgG and IgM) also fall, which is the reason for its infection precautions.
Trutakna comes as a single-dose prefilled autoinjector containing 150 mg. The dose is one injection under the skin once a week, given at home by the patient or a caregiver after training. The injection goes into the abdomen or thigh, using a different spot each time. The autoinjectors are kept in the refrigerator in their carton. Take one out 15 to 30 minutes before injecting so it can reach room temperature, without warming it in any other way. If needed, a pen can stay at room temperature for one stretch of up to 3 days, but then it should not go back in the refrigerator and must be discarded if not used. Do not use it if the liquid, normally clear to slightly hazy and brownish yellow, looks cloudy or has particles. If a dose is missed, inject it as soon as you remember, then continue once a week counting from that new day. Used pens go in a sharps container.
The most common side effect is a reaction where the shot was given, such as redness, swelling or tenderness. In the main study, about 30% of people on atacicept had some kind of injection site reaction, compared with 5% on placebo. Most side effects were mild or moderate and did not require stopping treatment. A severe injection site reaction is worth reporting to the care team. Infections, most often colds and other upper respiratory infections, were a little more common than with placebo (32% versus 28% of people had any infection). How to handle infections is covered under Interactions & Warnings. A serious allergic reaction to atacicept is possible. Signs such as hives, swelling of the lips, tongue or throat, trouble breathing or feeling faint after an injection need medical help right away, and anyone who has had a serious allergic reaction to the drug should not take it again.
Because atacicept lowers antibody production, it can make infections more likely, and a long-standing or repeated infection may become more serious. Treatment is usually postponed while an active infection is being treated. During treatment, contact the care team promptly about fever, chills, a worsening cough, painful urination or other signs of infection; the prescriber may pause the injections if an infection is serious. Vaccines need planning. Ideally, all recommended vaccines are brought up to date before starting; ask which of yours are live vaccines. Live vaccines, which contain a weakened form of the germ, are not recommended within 30 days before the first dose or at any time during treatment. Other vaccines may produce a weaker response. Taking atacicept with other medicines that suppress the immune system, including steroid pills such as prednisone, may raise infection risk further, and this combination has not been studied. Make sure every prescriber knows you take it. There is not enough information on use during pregnancy to judge the risk to a baby, and because of how it works, a baby exposed before birth could have a weakened immune system. Untreated IgAN also carries pregnancy risks, such as preeclampsia and early delivery, so anyone pregnant or planning pregnancy should weigh this with the kidney specialist. It is unknown whether the drug passes into breast milk.
Atacicept starts working on the immune system quickly. In the main study, the faulty IgA dropped within about 4 weeks, and protein in the urine fell gradually over the following months. At 36 weeks, people on atacicept had about 46% less urine protein than when they started, compared with about 7% less on placebo. Protein is usually followed with urine tests that compare protein with creatinine, a normal waste product, so results are not thrown off by how diluted the urine is. The bigger goal is to protect kidney function, measured by eGFR (estimated glomerular filtration rate), a blood test estimate of how much blood the kidneys filter each minute; lower numbers mean weaker kidneys. A final analysis of the same study, published in October 2026, found that eGFR stayed about level over a year on atacicept while it fell about 5.6 points on placebo, with the difference continuing through two years. That is an encouraging sign, but the FDA had not yet updated the label to reflect it, and longer follow-up is still needed. The drug is intended for ongoing weekly use alongside blood pressure control and other kidney care, with regular urine and blood tests and checks for infection. Responses vary, so the specialist will look at the trend in protein and eGFR over time to judge whether it is helping.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Trutakna (Atacicept), what you've noticed, or ask the community a question.